December 26, 2022
Eisai said on December 23 that it has commenced a data submission for a biologics license application in China for the investigational Alzheimer’s disease (AD) med lecanemab (BAN2401), an anti-amyloid beta (Aβ) protofibril antibody. The submission dossier includes data from...read more